Will the AstraZeneca share price be the largest FTSE 100 riser in 2021?

The AstraZeneca share price has performed well under Pascal Soriot. After its acquisition of Alexion, will it rise further in 2021?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Under Pascal Soriot, the AstraZeneca (LSE: AZN) share price has seen tremendous growth. In fact, in 2012 the share price was 3,000p, yet it saw highs of 9,600p in July this year. As such, the pharmaceutical company has, for a certain period of time, seen its market capitalisation overtake both Royal Dutch Shell and Unilever to top the FTSE 100.

But the past few months have been less favourable for the company. In fact, after news of its deal to buy Alexion for £29bn, its share price has fallen to 7,550p. This fall may be unjustified, however. Soriot believes the acquisition will aid the company in its growth over the next few years and allow it to regain its spot at the top of the FTSE 100. As such, as we head into 2021, are AstraZeneca shares the perfect buy? Yes and no!

The deal to buy Alexion

Despite the success of Soriot’s tenure, he’s not immune to criticism and came in for a lot of it over the decision to buy Alexion. Much of this revolved around overpayment. The offer price of $175 a share was at a 45% premium to Alexion’s closing price on the day. The firm is therefore now making its largest-ever acquisition and is required to secure a $17.5bn loan to help with payment. This will add to its already large debt pile — so no surprise that the AstraZeneca share price saw a 6% fall on the day the deal was announced.

There’s also a question of necessity. AstraZeneca already has a powerful portfolio and pipeline of different drugs and revenues were expected to grow as much as 33% by 2024. There are worries that this acquisition may disrupt its growth and is an unnecessary distraction (and expense).

But there are always two sides to the story. You see, there are also hopes that the deal could drive large gains in the AstraZeneca share price. Why? It will help AZN “enhance [its] presence in immunology”, while also strengthening cash generation. There are even reports the company could increase its dividend as a result. With a price-to-earnings ratio of under 10, Alexion was also fairly cheap in comparison to other pharma companies. As such, the acquisition could end up being a very shrewd move indeed.

Will the AstraZeneca share price be the largest riser?

Alongside this acquisition, there’s also plenty more news affecting the share price. For example, recent reports indicate the Oxford/AstraZeneca vaccine is to be approved in the UK within days. Although Soriot has agreed to supply the vaccine at cost price during the pandemic, meaning that the company will get no initial profits, this is still good news for its reputation and potential future profits.

Recently, AstraZeneca also released news that cancer drug Lynparza received approval from Japan’s regulator. This should also help boost profits.

As such, I believe that the AstraZeneca share price will rise in 2021 due to its enviable selection of various drugs and more-than-competent leadership. Although I’m not convinced by the deal to buy Alexion, AZN’s subsequent share price drop offers an opportunity to buy at a more reasonable price.

But to answer the question in the title of this piece, I don’t think it will be the largest riser in the FTSE 100 next year. For bigger gains, I’d consider either oil or bank stocks instead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stuart Blair owns shares in Royal Dutch Shell. The Motley Fool UK has recommended Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 resurgent cheap shares that could skyrocket in 2025

Cheap shares can take our portfolios to the next level. Here, Dr James Fox highlights two stocks that appear to…

Read more »

Investing Articles

How much does an investor need in a Stocks and Shares ISA to earn £1,000 a month in passive income?

A Stocks and Shares ISA's a valuable asset for investors. Not having to pay dividend tax can be a big…

Read more »

Investing Articles

9% dividend yield! Could buying this FTSE 250 stock earn me massive passive income?

Assura looks like an outstanding stock for dividend investors to consider. But is the 9% dividend yield the passive income…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Why I think this month could be critical for the Lloyds share price!

Our writer explains why he thinks the bank's 2024 results will have a significant impact on the short-term direction of…

Read more »

British Pennies on a Pound Note
Investing Articles

This former penny share has soared 168%. Is the best yet to come?

When Christopher Ruane saw a penny share as a potential bargain last year, he was spot on. So having not…

Read more »

Mature couple at the beach
Investing Articles

£20k in an ISA? Here’s how it could generate £1 of passive income every hour — forever

With a long-term approach, Christopher Ruane explains how an investor could aim to earn a pound per hour in passive…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

FTSE shares: overpriced or still a bargain?

Christopher Ruane reckons a storming FTSE 100 performance of late doesn't tell us much about whether there are still possible…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Would an investor have made money investing £2k in NIO stock 5 years ago?

Our writer looks at how NIO stock has performed over recent years and weighs the bull and bear cases as…

Read more »